GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » Other Operating Expense

Nicox (NICXF) Other Operating Expense : $0.31 Mil (TTM As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Nicox Other Operating Expense?

Nicox's Other Operating Expense for the six months ended in Jun. 2023 was $-0.27 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 was $0.31 Mil.

Nicox's quarterly Other Operating Expense increased from Jun. 2022 ($-0.36 Mil) to Dec. 2022 ($0.59 Mil) but then declined from Dec. 2022 ($0.59 Mil) to Jun. 2023 ($-0.27 Mil).

Nicox's annual Other Operating Expense declined from Dec. 2020 ($1.42 Mil) to Dec. 2021 ($1.30 Mil) and declined from Dec. 2021 ($1.30 Mil) to Dec. 2022 ($0.23 Mil).


Nicox Other Operating Expense Historical Data

The historical data trend for Nicox's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Other Operating Expense Chart

Nicox Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.03 0.93 1.42 1.30 0.23

Nicox Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 1.08 -0.36 0.59 -0.27

Nicox Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nicox Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Nicox's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox (NICXF) Business Description

Traded in Other Exchanges
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines